February 1st, 2023 | 20:29 CET
BioNTech, Defence Therapeutics, PAION - All dams broken
High price fluctuations due to approvals or successful test results are more the norm than the rule in the biotechnology sector. It is common for smaller stocks, in particular, to multiply within a few days. For example, the shares of Ambrx Biopharma increased by a whopping 1,000% within just one day, while the German biotech hopeful PAION doubled in price within a week. The next candidates for above-average performances are already waiting in the wings.
time to read: 3 minutes
|
Author:
Stefan Feulner
ISIN:
BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , PAION O.N | DE000A0B65S3
Table of contents:
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Defence Therapeutics - mRNA company with takeover fantasy
One of these promising companies that could soon become part of a big pharma's portfolio is Defence Therapeutics, which is significantly advancing research on mRNA vaccines in combination with its patented drug enhancer Accum. Recent news includes the issuance of a US patent on the use of Accum as a so-called drop-in enhancer to boost the immunogenicity and performance of virtually any cell-based or protein vaccine. Accum technology enables the precise transport of vaccine antigens or ADCs in the intact form to target cells. As a result, improved efficiency and efficacy against serious diseases such as cancer and infectious diseases can be achieved.
In cooperation with a European partner, mRNA vaccines against cancer developed in-house and combined with Accum technology are currently being compared with vaccines without Accum in a study. Defence Therapeutics wants to show that the efficacy can be significantly increased with the in-house technology. In parallel, Phase 1 studies are planned in the near future around skin cancer, lymphoma, breast cancer and colon cancer. More details can be found in a detailed report published this week.
February should also be exciting from a capital market perspective. Another industry meeting is scheduled in New York, where the Canadians will be available to answer questions from medical professionals and investors in two presentations. A wave of acquisitions is currently underway, as the pharmaceutical giants are sitting on bulging coffers on the one hand and are on the lookout for the latest innovations on the other. In January, for example, three deals worth more than USD 1 billion each were signed at the JP Morgan Healthcare Conference. Defence Therapeutics' market capitalization is CAD 151.40 million.
PAION - Explosion after recommendation
News from the European Medicines Agency's Committee for Medicinal Products for Human Use, CHMP, hit the stock market like a bomb. The expert panel published a positive opinion recommending approval of Remimazolam for the induction and maintenance of general anaesthesia in adults. It is now up to the European Commission to review the CHMP's recommendation. A final decision on the marketing authorization application for remimazolam in the EU is expected in the first half of 2023. In addition, the UK Medicines and Healthcare products Regulatory Agency (MHRA) also intends to review a potential marketing authorization in the UK.
Gregor Siebert, CEO of PAION AG, commented: "This positive opinion of the CHMP on Remimazolam brings us closer to our goal of offering the first innovative treatment option for anaesthesia in Europe for decades. We will make the necessary preparations to make the product available to patients and physicians for general anaesthesia in a timely manner, with a planned launch in the second half of 2023."
After an increase of more than 115%, the Paion share was able to leave the downward trend that had been developing since July 2020 and is currently trading at EUR 0.89. A setback to the trend mentioned above at EUR 0.75 would be healthy from a technical point of view.
BioNTech - The partner collapses
Bad news comes from the vaccine partner from the USA. Pfizer is feeling the waning Corona pandemic and thus the lower demand for vaccines. The Company forecasts a slump in sales of its COVID-19 preparations for the current fiscal year. In doing so, the US company undercut analysts' estimates, which were still too low. According to the report, sales of the vaccine marketed with BioNTech are expected to reach USD 13.5 billion, down 64% from 2022. Earnings are expected to be down by about 58%, amounting to USD 8 billion.
In contrast, analysts expected revenues of USD 14.4 billion with earnings of USD 10.3 billion. From a chart perspective, key support, the 2018 high at USD 44.05, has been breached. The next stop would now be the area around USD 41.50.
The volatilities from 2022 are likely to continue in biotech stocks in the current year. In addition, the number of acquisitions is steadily increasing. Defence Therapeutics is expected to attract interest from larger pharma companies with regard to its Accum technology. Pfizer disappointed with its outlook concerning the vaccine marketed with BioNTech.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
